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Abstract
Objective: To monitor the effects of raloxifene therapy on the uterus of postmenopausal women by transvaginal ultrasonography
and color flow Doppler. Methods: Twenty-five healthy postmenopausal women were enrolled in this prospective longitudinal
study performed at Department of Gynecology and Obstetrics, Faculty of Medicine of Ribeirão Preto. The patients were treated
with raloxifene hydrochloride (60 mg per day) for 6 months. All were submitted to transvaginal ultrasound examination with
color flow Doppler (ATL-HDI 3000 equipment) before the beginning and after 1, 3 and 6 months of treatment. Resistance
index (RI) and pulsatility index (PI) of the uterine arteries were determined by the Doppler method, being considered as
indicators of uterine perfusion. The following variables were analyzed: endometrial thickness, uterine volume, RI, and PI.
Data were analyzed statistically by repeated-measures analysis of variance. Results: Before treatment, endometrial thickness
was 3.38 ± 0.73 mm, and similar values were observed after 1, 3 and 6 months of treatment (3.04 ± 0.82; 3.3 ± 0.83; and
3.37 ± 0.79, respectively) (P > 0.05). No significant differences in uterine volume were observed between the pre- and
post-treatment periods. Uterine artery perfusion as indicated by RI and PI measured by Doppler also showed no significant
variation, with a high impedance flow being maintained throughout treatment. Conclusions: In the group studied here, raloxifene
treatment at the dose of 60 mg per day for 6 months did not induce significant changes in endometrial thickness, uterine
volume or uterine artery perfusion, confirming that short-term raloxifene treatment does not affect the uterus of postmenopausal
women.
© 2003 Published by Elsevier Ireland Ltd.
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1. Introduction
Over the last decades, great emphasis has been
placed on hormonal replacement therapy (HRT)
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during the postmenopausal period as an effective al-
ternative for the control of the effects of estrogen
deficiency. Studies have indicated that HRT relieves
vasomotor and urogenital symptoms, protects against
colorectal cancer, and improves bone density and
reduces the incidence of fractures [1–3]. However,
estrogen administration for many women has side ef-
fects and risks, a fact that impairs patient compliance
with the therapy proposed. Together with breast symp-
toms and the fear of cancer, genital bleeding is one
of the major causes of low compliance to treatment.
Other therapeutic options like selective estrogen re-
ceptor modulators (SERMs) have been used to avoid
these inconveniences and to improve patient compli-
ance, keeping the benefits of estrogens and minimiz-
ing their undesired effects. Raloxifene hydrochloride
is a so-called second-generation SERM, with an ac-
tion profile involving an estrogen agonist activity on
the bone tissue, but having no activity on breast [4,5].
In addition to beneficial effects on bone mineral den-
sity, raloxifene causes favorable changes in lipid pro-
file, with reduction of total cholesterol and low-density
lipoprotein cholesterol [6,7]. With respect to its effects
on the endometrium, several studies have indicated
the absence of undesirable stimulatory effects, with
no observation of significant changes in endometrial
thickness during the treatment with raloxifene [4,8].
However, the effects of raloxifene on blood perfusion
of the uterine arteries have not been well defined in
human. Therefore, the aim of the present study was to
establish the effects of raloxifene therapy on the uter-
ine arteries, endometrial thickness and uterine volume
in postmenopausal women, assessed by transvaginal
ultrasound and color flow Doppler.
2. Materials and methods
2.1. Patient population
Twenty-five healthy postmenopausal women were
enrolled in an open prospective longitudinal study. The
study was performed at the outpatient clinic of the De-
partment of Gynecology and Obstetrics, School Hos-
pital of Faculty of Medicine of Ribeirão Preto, Brazil.
Inclusion criteria were: age between 50 and 70 years,
last spontaneous menstrual cycle occurring more than
24 consecutive months before the study, presence of an
intact uterus without anomalies upon initial ultrasono-
graphic evaluation, no hormone replacement therapy
during the 90 days before the study, and agreement
of the patient to participate in the study after giving
written informed consent. The study was analyzed and
approved by the School Hospital Ethics Committee.
All subjects had a normal cardiac profile, no seri-
ous chronic disease, and were not taking any med-
ication that could interfere with Doppler evaluation.
Exclusion criteria were a previous or present history
of thromboembolic disorders, myocardial infarction,
coronary disease, stroke, hypertension, diabetes mel-
litus, hepatic or cholestatic diseases, severe depres-
sion, blood coagulation disorders, renal failure, and
estrogen-dependent neoplasia. Individuals with abnor-
mal genital bleeding of unknown cause were also ex-
cluded from the study. Other exclusion criteria were
smoking, alcoholism, obesity (body mass index equal
to or higher than 30 kg/m2), and the presence of sig-
nificant laboratory alterations in hepatic or renal func-
tions or any other clinically significant abnormal pre-
treatment result.
Before inclusion in the study group, the volun-
teers were submitted to a complete clinical evaluation
consisting of anamnesis and detailed physical exam-
ination, as well as complementary screening exams
as part of normal routine care during the climacteric
period. All patients presented serum 17-estradiol
<20 pg/ml, follicle-stimulating hormone >30 mIU/ml
and blood biochemistry (fasting glycemic, urea, crea-
tinine, bilirubins, lipid profile) within normal limits.
2.2. Study protocol
Eligible women were assigned to a daily dose of
60 mg of raloxifene hydrochloride (Eli Lilly and Com-
pany, Indianapolis, IN), 1 tablet per day. The following
variables were measured: endometrial thickness, uter-
ine volume, and the resistance and pulsatility indexes
of the uterine arteries using Doppler ultrasonography.
Ultrasonographic parameters were assessed before the
beginning and after 1, 3 and 6 months of treatment.
2.3. Ultrasonographic examination and
hemodynamic measurements
The ultrasonographic exams were carried out by the
same investigator who had a competence certificate
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and was experienced in the Doppler methodology.
An ultrasound system (HDI 3000; Advanced Tech-
nology Laboratory, USA) was used with a 9–5 MHz
endovaginal probe. In order to avoid possible circa-
dian interferences in the Doppler evaluation, the tests
were carried out during the same period of the day
(morning) in a silent, moderately illuminated and
air-conditioned room at a temperature of 23 ◦C. The
patients were told to completely empty the bladder and
to rest in dorsal decubitus for 10 min before examina-
tion. Patients were examined in the gynecological po-
sition with the back elevated 30◦ above the horizontal
plane.
The first part of the transvaginal ultrasonographic
examination consisted of Doppler analysis, since pro-
longed handling of the uterus may activate pelvic
circulation, thus compromising the evaluation. The
uterine artery was visualized laterally to the uterine
wall at the level of the internal ostium, by amplitude
Doppler. A 2-mm sample above each of the ascend-
ing branches of the uterine arteries was used. The
Doppler indexes were measured after obtaining at
least five similar flow rate waves of satisfactory qual-
ity. The impedance indexes used were resistance index
(RI = peak systolic-shifted frequency minus the end
diastolic-shifted frequency divided by the peak sys-
tolic) and pulsatility index (PI = peak systolic-shifted
frequency minus the end diastolic-shifted frequency
divided by the mean Doppler shift). Since the tech-
nique and experience of the investigator in obtain-
ing the Doppler indexes play an important role,
intra-observer variability of the method was deter-
mined by performing at least three measurements
of each index in each of the arterial segments
studied. The mean and standard deviation (SD) of
each index were calculated and used for statistical
analysis. The intra-observer coefficient of variation
(CV= [S.D./mean]× 100%) for each of the Doppler
indexes was calculated as the mean of the individual
CV obtained.
The second part of the transvaginal ultrasono-
graphic examination consisted of the analysis of the
endometrium and uterine volume. Endometrial thick-
ness, in mm, was determined as the distance between
an endometrium–myometrium interface and the op-
posite one. The uterine diameters were measured
on the longitudinal (D1), anteroposterior (D2) and
transverse (D3) planes, and the uterine volume (in
cm3) was calculated using the following formula:
D1×D2×D3× 0.52.
2.4. Statistical analysis
The non-parametric Kolmogorov–Smirnov test was
used to determine the normality of the distribution of
the values. The normality hypothesis was not rejected
for any of the variables. Since all variables showed a
normal distribution, analysis of variance for repeated
measures (ANOVA) was used to compare the values
obtained during the pretreatment period and those ob-
tained during the subsequent phases of the study, with
the level of significance set at 5%.
3. Results
The mean age of the patients was 56.0± 4.8 years
and the mean time after menopause was 8.3 ± 5.1
years. During pretreatment evaluation, the patients
showed a mean body mass index of 25.2± 3.7 kg/m2,
a waist/hip ratio of 0.81 ± 0.04 and mean sys-
tolic and diastolic pressures of 125.6 ± 17.2 and
80.5 ± 8.0 mmHg, respectively. Clinical follow-up
showed good treatment compliance in the study group.
Mean endometrial thickness at the pretreatment pe-
riod was 3.38± 0.73, a value considered to be within
the normal limit for postmenopausal women not using
HRT [9]. Raloxifene treatment did not show any sig-
nificant stimulatory effects, since endometrial thick-
ness was practically unaltered at 1, 3 and 6 months of
treatment (3.04± 0.82, 3.30± 0.83 and 3.37± 0.79,
respectively) (P > 0.05).
Uterine volume also did not show any significant
alterations during the 6-month follow-up period. Mean
uterine volume was 40.4 ± 17.8 cm3 at baseline and
similar values were observed at 1, 3 and 6 months of
treatment (40.4± 16.8, 40.2± 14.6 and 39.9± 14.4,
respectively).
Analysis of the blood perfusion parameters in the
uterine arteries by the Doppler method showed a high
flow impedance, as demonstrated by the elevated RI
and PI in these arteries during pretreatment evaluation.
Table 1 shows the RI and PI values of the uterine
arteries during the 6-month treatment with raloxifene.
No significant alterations were observed, with the high
impedance standard observed during the pretreatment
phase being maintained.
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Table 1
Resistance (RI) and pulsatility (PI) indexes of the uterine arteries
(UA) of postmenopausal women evaluated before and after 1, 3
and 6 months of raloxifene treatment
Pretreatment 1 month 3 months 6 months
Right UA
RI 0.92 ± 0.05 0.93 ± 0.05 0.93 ± 0.05 0.91 ± 0.04
PI 3.03 ± 0.81 3.27 ± 1.05 3.08 ± 0.73 2.98 ± 0.43
Left UA
RI 0.91 ± 0.06 0.92 ± 0.05 0.92 ± 0.05 0.91 ± 0.04
PI 2.85 ± 0.68 3.11 ± 1.06 3.03 ± 0.75 3.02 ± 0.68
No significant differences were observed between studied periods.
The Doppler method showed good reproducibility,
as indicated by the low intra-observer CV in terms of
RI (2.36%) and PI (7.5%). No statistically significant
differences were found between the measurements on
the right and left uterine arteries.
4. Discussion
Transvaginal ultrasonography provides high reso-
lution images, substantially improving the ability to
evaluate pelvic organs and to study morphological
changes in detail. With the use of high frequency
transducers, the endometrium can be assessed in terms
of echogenicity, regularity and thickness, so that this
method has become universally accepted as the ma-
jor tool for endometrial screening during the post-
menopausal period even in women who do not use
HRT. Several studies have been conducted to deter-
mine the normal ultrasonographic pattern of the en-
dometrium in postmenopausal women and an endome-
trial thickness of 4 mm or less is accepted by most in-
vestigators as being associated with a minimum risk
of endometrial disease [9,10].
In the present study, no significant changes in en-
dometrial thickness were observed during a period
of 6 months of raloxifene use. Reports from litera-
ture also show the safety of raloxifene with respect to
the endometrium [6,8]. Data from Multiple Outcomes
of Raloxifene Evaluation (MORE) trial confirmed the
hypothesis that raloxifene does not increase the risk
of endometrial hyperplasia or cancer [5]. Even when
higher doses than normally used were employed and
the effects on the uterus were evaluated using a more
extensive methodology, the results obtained for the
group treated with raloxifene did not differ from those
obtained for the placebo group [11,12].
With respect to uterine volume, again no signifi-
cant differences were observed between basal values
and the values determined during the study. Goldstein
et al. [11] demonstrated that raloxifene did not cause
significant changes in uterine volume, whereas a 22%
increase was observed in the group treated with estro-
gen. The increase in endometrial thickness and uterine
volume has also been reported after the use of tamox-
ifen [13–15].
Estrogen has a direct effect on the arteries, caus-
ing vasodilation [16]. This effect can be detected by
Doppler analysis of blood flow [17]. After menopause,
because of the hypoestrogenism occurring in women,
there is a reduction of the blood supply to pelvic or-
gans, resulting in important atrophy of the vaginal mu-
cosa and of the lower urinary tract, as well as reduction
of uterine and ovarian volume. During this phase in a
woman’s life, Doppler analysis of the uterine arteries
demonstrates high RI and PI, reflecting the existence
of high vascular resistance [18].
Several studies have demonstrated that estrogen
therapy during menopause causes significant changes
in blood perfusion of the uterine arteries and of other
arterial beds such as the carotids and cerebral arter-
ies. Thus, after the introduction of HRT, an increase
in uterine perfusion can be identified by the Doppler
technique, as demonstrated by marked reduction of
RI and PI of the uterine arteries [19,20]. In contrast
to the large amount of information about the vascular
actions of estrogens, little is known about the effects
of SERMs and of raloxifene in particular on the dif-
ferent vascular beds of the organism. Most available
data about SERMs exclusively refer to tamoxifen, in-
dicating an estrogen-like effect of the drug on uterine
perfusion [21,22].
An in vitro study in rabbit coronary arteries demon-
strated that raloxifene induces vasodilation by an
endothelium-dependent mechanism mediated by the
estrogen receptor, suggesting that this drug may acti-
vate the release of nitric oxide from endothelial cells
[23]. Another experimental study in sheep demon-
strated that intra-vaginal administration of raloxifene
provoked an acute increase in uterine blood flow from
20 to 220 ml/min, an effect also observed in the coro-
nary arteries and partially mediated by nitric oxide
[24]. An in vitro study using human umbilical vein
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cells demonstrated a stimulatory effect of raloxifene
on nitric oxide production in endothelial cells by an
acute mechanism of activation of the enzyme nitric
oxide synthetase depending on the estrogen receptor
[25].
However, few data are available in the literature
about studies in which human uterine perfusion was
evaluated by the Doppler method during treatment
with raloxifene. In recent report, Post et al. demon-
strated that compared with placebo, no significant
changes in the PI value of the uterine artery were
observed in the women using the currently marketed
dosage of 60 mg of raloxifene [26]. In the present
study, during treatment with raloxifene (60 mg per
day) for 6 months, we also did not observe significant
changes in any of the Doppler indexes, with the main-
tenance of a high vascular resistance in the uterine
arteries. The maintenance of high RI and PI suggests
that the treatment was virtually free of vasodilating
effects on the uterine arteries.
Although apparently opposing, our results do not
contradict those previous studies since they were con-
ducted using different methodologies, vascular beds
and animal species [23–25]. Within the SERM con-
cept, raloxifene presents variable effects according to
the region considered. On this basis, the vascular ef-
fects of the drug would also be expected to be tissue-
selective. It is also possible that the differences ob-
served between the effects of estrogen and raloxifene
on the uterine blood vessels and on the endometrium
and myometrium may be related to the differential ex-
pression of alpha and beta estrogen receptors in differ-
ent tissues, as well as to changes in the intra-cellular
processing of the ligand–receptor complex.
The results obtained on uterine perfusion is in agree-
ment with those concerning endometrial thickness and
uterine volume, since the absence of vascular effects
is assumed to have as consequence the absence of
effects on the development of endometrium and my-
ometrium. However, this apparently logic relation is
not universally accepted by researchers. We still do not
know whether there is a direct relationship between
the reduction in vascular resistance, increase on uter-
ine blood flow and the subsequent development of en-
dometrial hyperplasia and cancer, as it may occur in
postmenopausal women using non-opposed estrogen.
In conclusion, our results support the hypothesis
that raloxifene has no estrogen agonist activity on uter-
ine tissue when administered on a short-term and at
regular dose basis (60 mg per day).
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